Theory Paper IIIDrNB Cardiology – Theory Notes
CAROTID ARTERY STENTING (CAS): INDICATIONS AND EVIDENCE
ICURRENT INDICATIONS (ESC 2024 PAAD / ESVS 2023 GUIDELINES)
ASymptomatic Patients (TIA, Amaurosis Fugax, or Non-Disabling Ischemic Stroke Within 6 Months)
- Standard Revascularization Thresholds (NASCET Criteria): Revascularization is Class I recommended for 70% to 99% carotid stenosis and Class IIa for 50% to 69% stenosis, provided the documented procedural 30-day risk of death or stroke is less than 6 percent. (Carotid Endarterectomy [CEA] is generally first-line, while Carotid Artery Stenting [CAS] may be considered [Class IIb] as an alternative in standard-risk patients <70 years.)
- When CAS is Preferred Over CEA (Class IIa): CAS is preferred over open surgery in symptomatic patients with High Surgical Risk or Hostile Neck Anatomy—specifically prior cervical radiation therapy, radical neck dissection/tracheostomy, post-CEA restenosis, high carotid bifurcation or lesion extending above the C2 vertebral body (or low intrathoracic common carotid lesion), contralateral laryngeal/vocal cord paralysis, contralateral internal carotid occlusion, or severe cardiopulmonary comorbidity (severe HFrEF, recent MI, unstable angina).
BAsymptomatic Patients (No Ipsilateral Neurological Symptoms Within 6 Months)
- Standard Threshold (60% to 99% NASCET Stenosis): Routine revascularization is not recommended in unselected asymptomatic patients on modern medical therapy (statins, antiplatelets, BP control); revascularization (CEA [Class IIa] or CAS [Class IIb]) is considered only if 1 or more imaging/clinical features of increased ipsilateral stroke risk are present, the 30-day procedural stroke/death rate is less than 3 percent, and patient life expectancy exceeds 5 years.
- High-Risk Stroke Features Justifying Intervention in Asymptomatic 60–99% Stenosis: Contralateral TIA/stroke, silent ipsilateral infarction on brain CT/MRI, stenosis progression (>20%), large plaque area (>40–80 mm2) or echolucent/juxtaluminal black area on ultrasound, intraplaque hemorrhage or lipid-rich necrotic core on MRI, spontaneous microemboli on Transcranial Doppler (TCD), or impaired cerebrovascular reserve.
IICONTRAINDICATIONS TO CAROTID ARTERY STENTING
AAbsolute Contraindications
- Anatomical Factors: Visible free-floating intraluminal thrombus at the lesion site (extreme risk of fatal distal cerebral embolization during wiring/stenting), chronic total occlusion (100%) of the internal carotid artery, or inability to gain safe vascular access.
- Clinical Factors: Severe cognitive impairment/dementia, major disabling acute stroke (modified Rankin Scale >=3–4, or infarct involving >1/3 of the MCA territory due to high hemorrhagic transformation risk), intolerance to dual antiplatelet therapy, or life expectancy <1 year (or <5 years in asymptomatic stenosis).
BRelative Contraindications (Anatomical High-Risk for Transfemoral CAS [TF-CAS] — Favoring CEA or TCAR)
- Hostile Aortic Arch Anatomy: Type III aortic arch, severely calcified (“shaggy/porcelain”) aortic arch, or complex bovine arch requiring prolonged catheter manipulation across the arch.
- Lesion and Target Vessel Characteristics: Heavy circumferential (“eggshell” >=270–360 degree) calcification (prevents stent expansion), severe proximal common carotid or distal internal carotid tortuosity (>90-degree angulation / kinking) preventing embolic protection device placement, long multifocal tandem lesions, or echolucent unstable lipid-rich plaque.
- Patient Age >= 70 to 75 Years: Individual-patient meta-analyses of randomized trials (Carotid Stenting Trialists’ Collaboration) prove that transfemoral CAS carries approximately double the 30-day stroke risk of CEA in patients aged 70 years or older (driven by aortic arch atheroma scraping and vessel tortuosity), whereas CAS and CEA have equivalent stroke rates in patients under 70 years of age.
| Clinical Trial | Target Population & Design | Primary Efficacy & Safety Findings | Clinical Impact |
|---|---|---|---|
| SAPPHIRE (2004) | High-surgical-risk patients (symptomatic >=50% or asymptomatic >=80%): CAS + EPD vs. CEA | 1-yr composite (death, stroke, MI): 12.2% CAS vs. 20.1% CEA (non-inferior, p = 0.004) | Established CAS with embolic protection in high-surgical-risk patients |
| CREST (2010 & 10-Yr) | 2,502 Standard-risk symptomatic & asymptomatic patients: TF-CAS vs. CEA | 4-yr & 10-yr primary composite (stroke, MI, death): No difference (7.2% vs. 6.8%); 30-day Stroke higher in CAS (4.1% vs. 2.3%), while MI (2.3% vs. 1.1%) & cranial nerve palsy (4.7% vs. 0.3%) higher in CEA | Proved long-term durability of both; established the age <70 yr equivalence rule and MI vs. minor stroke trade-off |
| ACT-1 (2016) | 1,453 Standard-risk asymptomatic patients (<80 yr, 70–99% stenosis): CAS vs. CEA | 1-yr composite (death, stroke, MI): 3.8% CAS vs. 3.4% CEA (non-inferior); 5-yr stroke-free survival identical (93.1% vs. 94.7%) | Validated CAS non-inferiority in standard-risk asymptomatic patients <80 years |
| ACST-2 (2021) | 3,625 Asymptomatic patients (largest RCT): CAS vs. CEA | 30-day disabling stroke/death 1.0% in both (more non-disabling stroke with CAS: 2.7% vs. 1.6%); 5-year fatal/disabling stroke identical (2.5% vs. 2.5%) | Confirmed identical 5-year protection against disabling stroke |
| ROADSTER 1 & 2 | TCAR (Transcarotid Artery Revascularization) with dynamic flow reversal | 30-day stroke rate 1.4% (ROADSTER 1) and 0.6%–1.9% (ROADSTER 2); cranial nerve injury <1.5% | Bypassing the aortic arch via direct common carotid cutdown + flow reversal eliminates arch embolic stroke in elderly (>75 yr) patients |
IIIMANAGEMENT OF PROCEDURAL COMPLICATIONS
- Periprocedural Embolic Stroke:
- Prevention (Class IIa): Use of Cerebral Embolic Protection Devices (EPDs)—either Distal Filter Wire devices (e.g., FilterWire EZ, SpiderFX, Emboshield NAV6), Proximal Balloon Occlusion with Flow Reversal/Stasis (Mo.Ma Ultra—preferred in friable, thrombotic, or tight lesions), or Direct Transcarotid Flow Reversal (TCAR — ENROUTE system), alongside Dual-Layer Micromesh Stents (Roadsaver, CGuard) to prevent plaque prolapse through stent struts.
- Acute Management: Immediate cerebral angiography and mechanical neuro-thrombectomy (stent-retriever or aspiration) if acute large-vessel intracranial occlusion (M1/M2 MCA or terminal ICA) occurs on the table.
- Carotid Sinus Baroreceptor Reflex (Hemodynamic Depression — Bradycardia & Hypotension):
- Mechanism: Mechanical stretching of the carotid sinus baroreceptors during balloon predilation/postdilation stimulates the Sinus Nerve of Hering (CN IX) and nucleus tractus solitarius, triggering vagal bradycardia/asystole and sympathetic withdrawal hypotension (occurs in 10 to 40 percent).
- Management: Hold morning antihypertensives on the day of CAS, administer prophylactic Intravenous Atropine (0.5 to 1.0 mg IV) or glycopyrrolate 1 minute prior to balloon inflation across the carotid bulb, avoid aggressive balloon oversizing, and treat persistent post-stent baroreceptor hypotension with IV isotonic crystalloid boluses and IV Phenylephrine, Norepinephrine, or Dopamine (or oral Midodrine; usually resolves within 12 to 24 hours as baroreceptors reset).
- Cerebral Hyperperfusion Syndrome (CHS — Occurs in 1% to 3% at 12 Hours to 7 Days Post-CAS/CEA):
- Mechanism: In patients with chronic critical (>80–90%) carotid stenosis and contralateral occlusion or poor collateral flow, downstream cerebral arterioles are maximally chronically vasodilated with loss of pressure autoregulation. Sudden restoration of high-pressure pulsatile perfusion overwhelms the blood-brain barrier, causing ipsilateral hydrostatic vasogenic cerebral edema and fatal Intracerebral Hemorrhage (ICH).
- Clinical Triad: Severe ipsilateral throbbing frontotemporal headache, focal neurological deficits, and focal or generalized seizures (without cerebral ischemia on imaging).
- Management: Aggressive, immediate strict Blood Pressure Control (target Systolic BP <120 to 130 mmHg) using agents that do not cause cerebral vasodilation—specifically Intravenous Labetalol or Nicardipine/Clevidipine (strictly avoid Sodium Nitroprusside, Nitroglycerin, and Hydralazine, as direct cerebral venodilation/vasodilation increases intracranial pressure and worsens hyperperfusion).
IVPRACTICAL PROTOCOLS AND THE INDIAN CLINICAL CONTEXT
- Dual Antiplatelet Therapy (DAPT — Class I): Load with Aspirin (75–325 mg) + Clopidogrel (300–600 mg) prior to CAS, maintain DAPT (Aspirin 75–100 mg + Clopidogrel 75 mg daily) for at least 4 weeks (1 month) post-stenting until endothelialization, and continue lifelong single antiplatelet therapy (Clopidogrel or Aspirin) + High-Intensity Statin.
- The “14-Day Window” for Symptomatic Stenosis (Class I): Because the risk of recurrent stroke after a carotid TIA or minor stroke is highest in the first two weeks, carotid revascularization must be performed as early as possible—ideally within 14 days of symptom onset. (Note: During the hyperacute first 2 to 7 days after symptom onset, CEA carries a significantly lower stroke risk than transfemoral CAS because passing a wire/filter through a fresh, ruptured ulcerated plaque has a higher embolic hazard.)
- Practical Considerations in the Indian Context (Takayasu Arteritis): In young Indian patients (<40 years, predominantly female) with Takayasu Arteritis (Type I aortoarteritis) causing severe common or internal carotid stenosis, intervention must be deferred until active inflammation is suppressed with corticosteroids/immunosuppressants (normal ESR and hs-CRP). Because Takayasu lesions are dense, transmural, fibrotic pan-arteritic stenoses (unlike soft atherosclerotic plaques), they require high-pressure balloon angioplasty (preferring drug-coated/plain balloon angioplasty or selective stenting only for dissection/recoil, as routine stenting in Takayasu carries a higher rate of in-stent restenosis than in atherosclerosis).
Key references
- Mazzolai L, Teixido-Tura G, Lanzi S, et al.: 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases, European Heart Journal, 2024.
- Naylor R, Rantner B, Ancetti S, et al.: European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease, European Journal of Vascular and Endovascular Surgery, 2023.
- Brott TG, Hobson RW II, Howard G, et al. (CREST Investigators): Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis, New England Journal of Medicine, 2010 / 10-Year Results, NEJM, 2016.
- Halliday A, Bulbulia R, Bonati LH, et al. (ACST-2 Collaborative Group): Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy, The Lancet, 2021.
meritmedscript.comDr. Sidhartha Mullapudi
